Pancreatic Cancer Research

ResearcherJiangsu Province HospitalActive in the last 2 years

Junli Wu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0006-5564-9386; OpenAlex author ID A5103270793. Sources: OpenAlex.

Their work

Papers
25 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
64
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 3 papers · 2014: 2 papers · 2015: none · 2016: none · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: 5 papers · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: none · 2025: 5 papers · 2026: 1 paper

Papers 25

  1. Long-term outcomes of upfront pancreatectomy with venous resection for pancreatic cancer: a single-center, retrospective analysis. Co-author DOI 10.1097/js9.0000000000003617↗
  2. Comparison of Radical Antegrade Modular Pancreatosplenectomy Versus Standard Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Propensity Score Mat… Co-author DOI 10.1002/wjs.12630↗
  3. LIM domain only 7: a novel driver of immune evasion through regulatory T cell differentiation and chemotaxis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41418-024-01358-7↗
  4. Efficacy of second-line treatment for gemcitabine-refractory unresectable pancreatic cancer in a real-world setting. Co-author DOI 10.1186/s12885-025-14601-2↗
  5. Editorial expression of concern: Yin Yang-1 suppresses invasion and metastasis of pancreatic ductal adenocarcinoma by downregulating MMP10 in a MUC4/ErbB2/p38/… Co-author DOI 10.1186/s12943-025-02326-6↗
  6. Development and Validation of a Cell-Free DNA Fragmentomics-Based Model for Early Detection of Pancreatic Cancer. Co-author DOI 10.1200/jco.24.00287↗
  7. Prevalence of Germline Sequence Variations Among Patients With Pancreatic Cancer in China. Co-author DOI 10.1001/jamanetworkopen.2021.48721↗
  8. Sub-adventitial divestment technique for resecting artery-involved pancreatic cancer: a retrospective cohort study. Co-author DOI 10.1007/s00423-021-02080-5↗
  9. CA9-Related Acidic Microenvironment Mediates CD8+ T Cell Related Immunosuppression in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.832315↗
  10. Higher miR-543 levels correlate with lower STK31 expression and longer pancreatic cancer survival. Last author DOI 10.1002/cam4.3559↗
  11. Prognostic Nomogram for Resected Pancreatic Adenocarcinoma: A TRIPOD-Compliant Retrospective Long-Term Survival Analysis. Co-author DOI 10.1007/s00268-019-05325-z↗
  12. Glycolysis promotes the progression of pancreatic cancer and reduces cancer cell sensitivity to gemcitabine. Co-author DOI 10.1016/j.biopha.2019.109521↗
  13. EFNB2 facilitates cell proliferation, migration, and invasion in pancreatic ductal adenocarcinoma via the p53/p21 pathway and EMT. Co-author DOI 10.1016/j.biopha.2020.109972↗
  14. [Comparison of radical antegrade modular pancreatosplenectomy with conventional distal pancreatectomy for pancreatic adenocarcinoma of the body and tail]. Co-author DOI 10.3760/cma.j.cn112139-20200413-00301↗
  15. Central pancreatectomy for early-stage pancreatic ductal adenocarcinoma: a single-center case-control study. Co-author DOI 10.1007/s00423-019-01766-1↗
  16. Activation of PPARα by clofibrate sensitizes pancreatic cancer cells to radiation through the Wnt/β-catenin pathway. Co-author DOI 10.1038/onc.2017.401↗
  17. Predictors of distant metastasis on exploration in patients with potentially resectable pancreatic cancer. Co-author DOI 10.1186/s12876-018-0891-y↗
  18. MicroRNA-217 inhibits cell proliferation, invasion and migration by targeting Tpd52l2 in human pancreatic adenocarcinoma. Co-author DOI 10.3892/or.2017.6036↗
  19. Elevation of MMP-9 and IDO induced by pancreatic cancer cells mediates natural killer cell dysfunction. Co-author DOI 10.1186/1471-2407-14-738↗
  20. Yin Yang-1 suppresses invasion and metastasis of pancreatic ductal adenocarcinoma by downregulating MMP10 in a MUC4/ErbB2/p38/MEF2C-dependent mechanism. Co-author DOI 10.1186/1476-4598-13-130↗
  21. MAP3K10 promotes the proliferation and decreases the sensitivity of pancreatic cancer cells to gemcitabine by upregulating Gli-1 and Gli-2. Co-author DOI 10.1016/j.canlet.2012.11.005↗
  22. Comprehensive analysis of the percentage of surface receptors and cytotoxic granules positive natural killer cells in patients with pancreatic cancer, gastric … Co-author DOI 10.1186/1479-5876-11-262↗
  23. CEACAM6 induces epithelial-mesenchymal transition and mediates invasion and metastasis in pancreatic cancer. Co-author DOI 10.3892/ijo.2013.2015↗
  24. Association of increased DNA methyltransferase expression with carcinogenesis and poor prognosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s12094-012-0770-x↗
  25. Galectin-1 secreted by activated stellate cells in pancreatic ductal adenocarcinoma stroma promotes proliferation and invasion of pancreatic cancer cells: an i… Co-author DOI 10.1097/mpa.0b013e318217945e↗

Closest collaborators

The 25 strongest of 64 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kuirong Jiang · 18 shared papers, 2011–2026 · strength 1.89
  2. Wentao Gao · 18 shared papers, 2011–2026 · strength 1.83
  3. Jishu Wei · 15 shared papers, 2011–2025 · strength 1.64
  4. Yi Miao · 16 shared papers, 2011–2025 · strength 1.55
  5. Zipeng Lu · 10 shared papers, 2011–2026 · strength 1.34
  6. Min Tu · 9 shared papers, 2013–2026 · strength 1.27
  7. Yunpeng Peng · 9 shared papers, 2013–2025 · strength 0.99
  8. Lingdi Yin · 6 shared papers, 2019–2025 · strength 0.80
  9. Yi Miao · 6 shared papers, 2013–2025 · strength 0.60
  10. Xumin Huang · 3 shared papers, 2020–2026 · strength 0.56
  11. Kuirong Jiang · 3 shared papers, 2013–2025 · strength 0.50
  12. Pengfei Wu · 2 shared papers, 2025–2026 · strength 0.47
  13. Kai Zhang · 2 shared papers, 2025–2026 · strength 0.47
  14. Jie Yin · 2 shared papers, 2025–2026 · strength 0.47
  15. Qiuyang Chen · 4 shared papers, 2017–2025 · strength 0.46
  16. Baobao Cai · 4 shared papers, 2013–2025 · strength 0.46
  17. Shangnan Dai · 3 shared papers, 2020–2025 · strength 0.43
  18. Guangfu Wang · 3 shared papers, 2019–2025 · strength 0.42
  19. Zekuan Xu · 7 shared papers, 2011–2025 · strength 0.40
  20. Chunhua Xi · 3 shared papers, 2021–2022 · strength 0.34
  21. Hao Gao Gao · 3 shared papers, 2019–2022 · strength 0.34
  22. Zhuyin Qian · 5 shared papers, 2011–2025 · strength 0.33
  23. Qiang Li · 5 shared papers, 2011–2022 · strength 0.32
  24. Kai Zhang · 3 shared papers, 2019–2022 · strength 0.32
  25. Jian‐Min Chen · 2 shared papers, 2022–2025 · strength 0.29

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.